Non ST Segment Elevation (NSTEMI) Myocardial Infarction

Article Author:
Hajira Basit
Article Author (Archived):
Ahmad Malik
Article Editor:
Martin Huecker
Updated:
5/4/2019 9:20:06 PM
PubMed Link:
Non ST Segment Elevation (NSTEMI) Myocardial Infarction

Introduction

Acute coronary syndrome (ACS) can be divided into subgroups of ST-segment elevation myocardial infarction (STEMI), non-ST-segment elevation myocardial infarction (NSTEMI), and unstable angina. ACS carries significant morbidity and mortality and the prompt diagnosis, and appropriate treatment is essential. STEMI diagnosis and management are discussed elsewhere. NSTEMI and Unstable angina are very similar, with NSTEMI having positive cardiac biomarkers. The presentation, diagnosis, and management of NSTEMI are discussed below.[1][2][3]

Etiology

The etiology of NSTEMI varies as there are several potential causes.

Epidemiology

The median age at the time of presentation for ACS in the United States is 68 years. Males outnumber females by a 3:2 ratio. The incidence of ACS in the United States is over 780,000, and of those, approximately 70% will have NSTEMI.

Pathophysiology

ACSs are simply a mismatch in the myocardial oxygen demand and myocardial oxygen consumption. While the cause of this mismatch in STEMI is nearly always coronary plaque rupture resulting thrombosis formation occluding a coronary artery, there are several potential causes of this mismatch in NSTEMI. There may be a flow-limiting condition such as a stable plaque, vasospasm as in Prinzmetal angina, coronary embolism, or coronary arteritis. Non-coronary injury to the heart such as cardiac contusion, myocarditis, or presence of cardiotoxic substances can also produce NSTEMI. Finally, conditions relatively unrelated to the coronary arteries or myocardium itself such as hypotension, hypertension, tachycardia, aortic stenosis, and pulmonary embolism lead to NSTEMI because the increased oxygen demand cannot be met.[4][5]

History and Physical

The “typical” presentation of NSTEMI is a pressure-like substernal pain, occurring at rest or with minimal exertion. The pain generally lasts more than 10 minutes and may radiate to either arm, the neck, or the jaw.  The pain may be associated with dyspnea, nausea or vomiting, syncope, fatigue, or diaphoresis. Sudden onset of unexplained dyspnea with or without associated symptoms is also a common presentation. Risk factors for ACS include male sex, older age, family history of coronary artery disease, diabetes, personal history of coronary artery disease, and renal insufficiency. Atypical symptoms may include a stabbing or pleuritic pain, epigastric or abdominal pain, indigestion, and isolated dyspnea. While all patients presenting with ACS are more likely to present with typical symptoms than atypical symptoms, the likelihood of atypical presentations increases with age over 75, women and those with diabetes, renal insufficiency, and dementia.  

Physical Exam for ACS and NSTEMI is often nonspecific. Clues such as back pain with aortic dissection or pericardial friction rub with pericarditis may point to an alternative diagnosis for a patient’s chest pain, but no such exam finding exists that indicates ACS as the most likely diagnosis. Signs of heart failure should increase concern for ACS but are, again, nonspecific findings.[6][7][8]

Evaluation

History, ECG, and cardiac biomarkers are the mainstays in the evaluation. An ECG should be performed as soon as possible in patients presenting with chest pain or those with a concern for ACS. A normal ECG does not exclude ACS and NSTEMI. ST elevation or anterior ST depression should be considered a STEMI until proven otherwise and treated as such. Findings suggestive of NSTEMI include transient ST elevation, ST depression, or new T wave inversions. ECG should be repeated at predetermined intervals or if symptoms return.

Cardiac troponin is the cardiac biomarker of choice. Troponin is more specific and more sensitive than other biomarkers and becomes elevated relatively early in the disease process. While contemporary cardiac troponin may not be elevated within the first 2 to 4 hours after symptom onset, newer high sensitivity troponin assays have detectable elevations much earlier. It is also true that the amount of troponin released, and therefore the time to elevation, is proportional with infarct size, so it is unlikely to have a negative initial troponin with larger infarcts. Regardless of infarct size, most patients with true ischemia will have elevations in troponin within 6 hours, and negative troponins at this point effectively rule out infarct in most patients.  Most assays use a cutoff value of greater than a 99th percentile as a positive test. In older, contemporary troponin assays, no detectable troponin is reported in most healthy individuals without the disease.  Newer high sensitivity troponin assays often will report a normal detectable range in healthy individuals without the disease. 

Several tools and scores have been developed to assist in the workup of ACS. These tools must be used with caution and in the appropriate context as none have been definitively shown to be superior to clinician judgment. Some common tools available are the TIMI (Thrombolysis In Myocardial Infarction) risk score, the GRACE (Global Registry of Acute Coronary Events) risk score, the Sanchis score, the Vancouver rule, HEART (History, ECG, Age, Risk Factors, and Troponin) score, HEARTS3 score, and Hess prediction rule. The HEART score was specifically developed for emergency department patients and has gained popularity in this setting. 

Diagnosis 

NSTEMI is diagnosed in patients determined to have symptoms consistent with ACS and troponin elevation but without ECG changes consistent with STEMI. Unstable angina and NSTEMI differ primarily in the presence or absence of detectable troponin leak. 

Treatment / Management

Initial management strategies aim to reduce cardiac ischemia and prevent death. Oxygen, aspirin, and nitrates are administered based on initial concern for ACS and prior to definitive diagnosis. Subsequent treatment depends on confirmation of diagnosis or high index of suspicion with or without definitive diagnosis. [1][9][10][11][12]

Oxygen was previously recommended for all patients presenting with concern for ACS, but newer data suggests this strategy may be harmful in patients who otherwise do not warrant supplemental oxygen. Supplemental oxygen is now recommended in patients with oxygen saturation less than 90%, those with respiratory distress, or when high risk features of hypoxemia are present. 

Chewable, non-coated, aspirin 324 mg should be given to all patients who present with concern for ACS unless otherwise contraindicated.  Patients who cannot take aspirin may be given Clopidogrel 300-600 mg or Ticagrelor 180 mg as a loading dose for antiplatelet therapy. 

Patients with ongoing symptoms should receive 0.4 mg sublingual nitroglycerin every 5 minutes for up to three doses or until pain is relieved, unless otherwise contraindicated. Contraindications include recent use of phosphodiesterase inhibitors and hypotension. Nitrates should be used with extreme caution in patients with concern for right sided infarction. Continuous intravenous nitroglycerin should be considered in patients with persistent signs of heart failure or hypertension.

Many patients will present with concern for ACS but will not have positive findings of ischemic ECG changes or positive troponin on initial workup. These patients may be observed with serial ECG and troponin measurements every 3 to 6 hours. Patients also may undergo provocative testing such as the treadmill stress test or myocardial perfusion imaging prior to discharge or within 72 hours. Low risk patients often may be discharged with referral for further outpatient testing after initial ACS is ruled out.

In patients where NSTEMI has been definitively diagnosed or is highly likely, anticoagulation should be initiated. Protocols will vary by institution, so cardiology consultation should be obtained if readily available. This is especially true when there is the possibility of percutaneous intervention, as this may change anticoagulation strategies. Unfractionated heparin with bolus dosing and continuous infusion is commonly used, with most institutions having protocols available. Other strategies may include the use of enoxaparin, bivalirudin, fondaparinux, and dual antiplatelet therapies. Fibrinolytic therapies should not be used in NSTEMI. 

When NSTEMI has been diagnosed, patients should be admitted to cardiac care units for further management. Beta blocker therapy should be started within 24 hours after presentation in patients who do not have a contraindication. Contraindications include signs of heart failure, hypotension, heart conduction block, or reactive airway disease. Unless otherwise contraindicated, ACE Inhibitors should be initiated in patients with an ejection fraction less than 40%, hypertension, diabetes, or chronic kidney disease. High-dose statins should be initiated for cholesterol management. Invasive and non-invasive testing strategies are employed. Both early intervention strategies with diagnostic angiography and intervention are applied as indicated, and conservative medical management strategies are employed. The rationale for choosing one strategy over the other is often patient and institution specific and beyond the scope of this review.

Enhancing Healthcare Team Outcomes

The diagnosis and management of NSTEMI is with an interprofessional team that consists of a cardiologist, internist, nurse practitioner, and a pharmacist.

In patients where NSTEMI has been definitively diagnosed or is highly likely, anticoagulation should be initiated. Protocols will vary by institution, so cardiology consultation should be obtained if readily available. This is especially true when there is the possibility of percutaneous intervention, as this may change anticoagulation strategies. 

When NSTEMI has been diagnosed, patients should be admitted to cardiac care units for further management. Beta-blocker therapy should be started within 24 hours after presentation in patients who do not have a contraindication. Unless otherwise contraindicated, ACE Inhibitors should be initiated in patients with an ejection fraction less than 40%, hypertension, diabetes, or chronic kidney disease. High-dose statins should be initiated for cholesterol management. Invasive and non-invasive testing strategies are employed. Both early intervention strategies with diagnostic angiography and intervention are applied as indicated, and conservative medical management strategies are employed. 

The outcomes of patients with NSTEMI depend on the severity of myocardial injury, compliance with treatment and other comorbidity. Patients who do not change their risk factors for coronary disease have a poor outcome.[13][14] (Level V)


References

[1] Gilutz H,Shindel S,Shoham-Vardi I, Adherence to NSTEMI Guidelines in the Emergency Department: Regression to Reality. Critical pathways in cardiology. 2019 Mar;     [PubMed PMID: 30747764]
[2] Piątek Ł,Wilczek K,Janion-Sadowska A,Gierlotka M,Gąsior M,Sadowski M, Outcomes of a routine invasive strategy in elderly patients with non-ST-segment elevation myocardial infarction from 2005 to 2014: results from the PL-ACS registry. Coronary artery disease. 2019 Feb 4;     [PubMed PMID: 30724817]
[3] Manfredonia L,Lanza GA,Crudo F,Lamendola P,Graziani F,Villano A,Locorotondo G,Melita V,Mencarelli E,Pennestrì F,Lombardo A,De Vita A,Ravenna SE,Bisignani A,Crea F, Diagnostic role of echocardiography in patients admitted to the emergency room with suspect no-ST-segment elevation acute myocardial infarction. European review for medical and pharmacological sciences. 2019 Jan;     [PubMed PMID: 30720191]
[4] Rupprecht HJ,Geeren M,Geeren M,Weilemann S,Schuster HP, [Acute coronary syndrome without ST-elevation (NSTE-ACS)]. Herz. 2019 Feb;     [PubMed PMID: 30627742]
[5] Kamińska J,Koper OM,Siedlecka-Czykier E,Matowicka-Karna J,Bychowski J,Kemona H, The utility of inflammation and platelet biomarkers in patients with acute coronary syndromes. Saudi journal of biological sciences. 2018 Nov;     [PubMed PMID: 30505168]
[6] Sriha Belguith A,Beltaief K,Msolli MA,Bouida W,Abroug H,Ben Fredj M,Zemni I,Grissa MH,Boubaker H,Hsairi M,Nouira S, Management of acute coronary syndrome in emergency departments: a cross sectional multicenter study (Tunisia). BMC emergency medicine. 2018 Dec 3;     [PubMed PMID: 30509187]
[7] Lemkes JS,Janssens GN,van der Hoeven NW,van de Ven PM,Marques KMJ,Nap A,van Leeuwen MAH,Appelman YEA,Knaapen P,Verouden NJW,Allaart CP,Brinckman SL,Saraber CE,Plomp KJ,Timmer JR,Kedhi E,Hermanides RS,Meuwissen M,Schaap J,van der Weerdt AP,van Rossum AC,Nijveldt R,van Royen N, Timing of revascularization in patients with transient ST-segment elevation myocardial infarction: a randomized clinical trial. European heart journal. 2019 Jan 14;     [PubMed PMID: 30371767]
[8] Arora S,Stouffer GA,Kucharska-Newton A,Vaduganathan M,Qamar A,Matsushita K,Kolte D,Reynolds HR,Bangalore S,Rosamond WD,Bhatt DL,Caughey MC, Fifteen-Year Trends in Management and Outcomes of Non-ST-Segment-Elevation Myocardial Infarction Among Black and White Patients: The ARIC Community Surveillance Study, 2000-2014. Journal of the American Heart Association. 2018 Oct 2;     [PubMed PMID: 30371336]
[9] Puymirat E,Bonaca M,Fumery M,Tea V,Aissaoui N,Lemesles G,Bonello L,Ducrocq G,Cayla G,Ferrières J,Schiele F,Simon T,Danchin N, Atherothrombotic risk stratification after acute myocardial infarction: The Thrombolysis in Myocardial Infarction Risk Score for Secondary Prevention in the light of the French Registry of Acute ST Elevation or non-ST Elevation Myocardial Infarction registries. Clinical cardiology. 2019 Feb;     [PubMed PMID: 30536449]
[10] Güntekin Ü,Tosun V,Kilinç AY,Saydam G,Korucuk N,Bozdemir MN, ST segment elevation myocardial infarction (STEMI) patients are more likely to achieve lipid-lowering treatment goals: A retrospective analysis of patients presenting with first acute coronary syndromes. Medicine. 2018 Sep;     [PubMed PMID: 30278492]
[11] Sanchis J,Ariza-Solé A,Abu-Assi E,Alegre O,Alfonso F,Barrabés JA,Baz JA,Carol A,Díez Villanueva P,García Del Blanco B,Elízaga J,Fernandez E,García Del Egido A,García Picard J,Gómez Blázquez I,Gómez Hospital JA,Hernández-Antolín R,Llibre C,Marín F,Martí Sánchez D,Martín R,Martínez Sellés M,Miñana G,Morales Gallardo MJ,Núñez J,Pérez de Prado A,Pinar E,Sanmartín M,Sionis A,Villa A,Marrugat J,Bueno H, Invasive Versus Conservative Strategy in Frail Patients With NSTEMI: The MOSCA-FRAIL Clinical Trial Study Design. Revista espanola de cardiologia (English ed.). 2019 Feb;     [PubMed PMID: 29525724]
[12] Bønaa KH,Steigen T, Coronary angiography in non-ST-elevation acute myocardial infarction - whom and when? Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke. 2017 Nov 28;     [PubMed PMID: 29181952]
[13] Harrington DH,Stueben F,Lenahan CM, ST-Elevation Myocardial Infarction and Non-ST-Elevation Myocardial Infarction: Medical and Surgical Interventions. Critical care nursing clinics of North America. 2019 Mar;     [PubMed PMID: 30736935]
[14] Held EP,Henry TD, When small vessels become big problems! Microvascular dysfunction in NSTEMI. Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography     [PubMed PMID: 30478884]